Trials / Completed
CompletedNCT02678286
Evaluation of N1539 Following Abdominoplasty Surgery
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Efficacy and Safety of N1539 Following Abdominoplasty Surgery
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Baudax Bio · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the analgesic efficacy of N1539 in subjects with acute moderate to severe pain following abdominoplasty surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | N1539 | |
| DRUG | Intravenous Placebo |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2016-10-01
- Completion
- 2016-11-01
- First posted
- 2016-02-09
- Last updated
- 2018-02-14
- Results posted
- 2018-02-14
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02678286. Inclusion in this directory is not an endorsement.